Research programme: HDL-related therapeutics - Esperion
Alternative Names: ESP-15228; HDL elevatorsLatest Information Update: 04 Nov 2017
At a glance
- Originator Esperion Therapeutics
- Class Organic chemicals; Peptides; Small molecules
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Dyslipidaemias
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (PO)
- 22 Jun 2010 Esperion establishes technology supply agreement with TransGenRx